Amryt Pharma plc Stock London S.E.

Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.